Stock COGT COGENT BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
6.96 USD -2.25% Intraday chart for Cogent Biosciences, Inc. +7.74% +18.37%
Feb. 27 North American Morning Briefing : Stock Futures -2- DJ
Feb. 26 Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)
PR
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
AQ
North American Morning Briefing : Stock Futures -2-
DJ
Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating
MT
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
AQ
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14
MT
Transcript : Cogent Biosciences, Inc. - Special Call
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating
MT
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
AQ
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
CI
Top Midday Gainers
MT
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump
MT
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
AQ
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target
MT
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
AQ
Transcript : Cogent Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024
MT
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COGT Stock
  4. News Cogent Biosciences, Inc.